- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1/PD-L1 in disease
Authors
Keywords
-
Journal
Immunotherapy
Volume 10, Issue 2, Pages 149-160
Publisher
Future Medicine Ltd
Online
2017-12-20
DOI
10.2217/imt-2017-0120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- The mechanisms tumor cells utilize to evade the host's immune system
- (2017) Nyanbol Kuol et al. MATURITAS
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers
- (2017) Po-Lin Lin et al. Cancer Medicine
- PD1 Negative and PD1 Positive CD4+ T Regulatory Cells in Mild Cognitive Impairment and Alzheimer's Disease
- (2017) Marina Saresella et al. JOURNAL OF ALZHEIMERS DISEASE
- Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab
- (2016) A. Heine et al. ANNALS OF ONCOLOGY
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
- (2016) Wojciech G. Lesniak et al. BIOCONJUGATE CHEMISTRY
- Atezolizumab: First Global Approval
- (2016) Anthony Markham DRUGS
- Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma
- (2016) Michael C. Kirchberger et al. EUROPEAN JOURNAL OF CANCER
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- PD-1/PD-L1 blockage in cancer treatment—from basic research to clinical application
- (2016) Masaki Mandai International Journal of Clinical Oncology
- Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
- (2016) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-Inhibition
- (2016) H. Oppel-Heuchel et al. UROLOGE
- Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-Inhibition
- (2016) H. Oppel-Heuchel et al. UROLOGE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
- (2016) Samit Chatterjee et al. Oncotarget
- PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient
- (2016) Zhenhua Li et al. Journal of Cancer
- Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases
- (2016) Yan Yang et al. Journal of Thoracic Disease
- PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
- (2016) Shamaila Munir Ahmad et al. OncoImmunology
- Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn’s disease
- (2016) Jack Robertson et al. Scientific Reports
- Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
- (2015) Su-Jin Shin et al. ANNALS OF SURGICAL ONCOLOGY
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies
- (2015) S. Heskamp et al. CANCER RESEARCH
- Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
- (2015) Anders Josefsson et al. CANCER RESEARCH
- Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes
- (2015) R. Fujisawa et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
- (2015) Cuiping Liu et al. ARTHRITIS RESEARCH & THERAPY
- Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
- (2015) Yi Qing et al. Drug Design Development and Therapy
- The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
- (2015) Xinbing Sui et al. Oncotarget
- Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
- (2015) Ziming Du et al. Oncotarget
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
- (2015) Jie Zhang et al. Thoracic Cancer
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
- (2015) K. M. Mahoney et al. Cancer Immunology Research
- PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization
- (2015) B. T. Rekoske et al. Cancer Immunology Research
- 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
- (2015) Paolo A. Ascierto et al. EBioMedicine
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- The PD-1/PD-Ls pathway and autoimmune diseases
- (2014) Suya Dai et al. CELLULAR IMMUNOLOGY
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells
- (2014) J J Pen et al. GENE THERAPY
- Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype
- (2014) Federico Garrido et al. INTERNATIONAL JOURNAL OF CANCER
- Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy
- (2014) W.-S. Chang et al. JOURNAL OF IMMUNOLOGY
- Essential Role of Program Death 1-Ligand 1 in Regulatory T-Cell–Afforded Protection Against Blood–Brain Barrier Damage After Stroke
- (2014) Peiying Li et al. STROKE
- Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions
- (2014) Frederique M Moret et al. ARTHRITIS RESEARCH & THERAPY
- Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
- (2014) Shangfeng Zhao et al. Frontiers in Cellular Neuroscience
- Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation
- (2014) Lisa Scandiuzzi et al. Cell Reports
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- PD-L1 expression and tumor-infiltrating lymphocytes
- (2014) Kurt A Schalper OncoImmunology
- The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
- (2014) Joanne Leung et al. Immune Network
- PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4 + T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes
- (2013) Kristen E. Pauken et al. DIABETES
- B7 family checkpoint regulators in immune regulation and disease
- (2013) Sabrina Ceeraz et al. TRENDS IN IMMUNOLOGY
- Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
- (2013) R. W. Joseph et al. Cancer Immunology Research
- PD-1 targeting in cancer immunotherapy
- (2012) Robert Ferris CANCER
- Immune checkpoints in central nervous system autoimmunity
- (2012) Nicole Joller et al. IMMUNOLOGICAL REVIEWS
- Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17β-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+regulatory T cells
- (2012) Sheetal Bodhankar et al. IMMUNOLOGY
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells
- (2011) Sheetal Bodhankar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease
- (2011) Marina Saresella et al. NEUROBIOLOGY OF AGING
- Programmed Death-1 Pathway Limits Central Nervous System Inflammation and Neurologic Deficits in Murine Experimental Stroke
- (2011) Xuefang Ren et al. STROKE
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells
- (2010) Carolin Brandl et al. PLoS One
- Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease
- (2009) D. Trabattoni et al. JOURNAL OF IMMUNOLOGY
- Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade
- (2009) E. D. Reynoso et al. JOURNAL OF IMMUNOLOGY
- Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9
- (2009) Maya Koronyo-Hamaoui et al. JOURNAL OF NEUROCHEMISTRY
- Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis
- (2009) Ling Chen et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- Protective Role of Programmed Death 1 Ligand 1 (PD-L1)in Nonobese Diabetic Mice: The Paradox in Transgenic Models
- (2008) C.-J. Wang et al. DIABETES
- PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE
- (2008) Bettina Schreiner et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1
- (2008) Chunhe Wang et al. IMMUNOLOGY
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started